View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
May 17, 2022

Hepatitis C accounts for 0.9% share of global Infectious Disease clinical trial activity in 2021

By Carmen

Hepatitis C accounted for a 0.9% share of the global clinical trials within the Infectious Disease therapy area in 2021, registering a decrease of 9.4% when compared with the last ten-year average of 10.3% share, according to GlobalData.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Non-industry sponsored trials outnumber industry sponsored trials for Hepatitis C

Industry sponsored trials held a 42.9% share of all the clinical trials for Hepatitis C indication in 2021, registering a decrease of 5.4% when compared with the ten-year average of 48.3%. Non-industry sponsored trials accounted for a 57.1% share in 2021, registering an increase of 5.4% over the ten-year average of 51.7%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Top regions of industry sponsored Hepatitis C trials

North America was the top region for industry sponsored Hepatitis C trials, accounting for a 53.3% share in 2021, when compared with the five-year average of 18.3% and ten-year average of 37.9%.

Asia-Pacific was at the second position with a 26.7% share in 2021, over the five-year average of 66.0% and ten-year average of 51.0%, followed by Europe with a 26.7% share in 2021, as against five-year and ten-year averages of 28.6% and 38.6% respectively.

Middle East and Africa stood fourth with a 6.7% share in 2021, compared with the five-year average of 6.3% and ten-year average of 7.4%, followed by South and Central America with a 0.0% share in 2021, over five-year and ten-year averages of 1.4% and 3.6% respectively.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Canada was the top country for industry sponsored Hepatitis C trials, accounting for a 40.0% share in 2021, as against the five-year average of 7.0% and ten-year average of 12.5%.

The US held a 20.0% share in 2021, over the five-year average of 14.5% and ten-year average of 34.4%, followed by China with a 20.0% share in 2021, compared with the five-year and ten-year averages of 36.7% and 20.6% respectively.

Australia held a 6.7% share in 2021, as against the five-year average of 7.3% and ten-year average of 11.6%.

Austria held a 6.7% share in 2021, over the five-year and ten-year averages of 0.4% and 3.8% respectively.

Top regions of non-industry sponsored Hepatitis C trials

Asia-Pacific was the top region for non-industry sponsored Hepatitis C trials, accounting for a 50.0% share in 2021 when compared with the five-year average of 42.2% and ten-year average of 42.8%.

Europe was at the second position with a 20.0% share in 2021, over the five-year and ten-year averages of 14.0% and 20.6% respectively, followed by North America with a 20.0% share in 2021, as against the five-year average of 25.5% and ten-year average of 23.3%.

Middle East and Africa stood at the fourth position with a 10.0% share in 2021, compared with the five-year average of 20.3% and ten-year average of 13.5%, followed by South and Central America with a 5.0% share in 2021, over the five-year and ten-year averages of 1.2% and 1.6% respectively.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

The US was the top country for non-industry sponsored Hepatitis C trials, accounting for a 20.0% share in 2021, as against the five-year average of 24.0% and ten-year average of 21.3%.

China held a 15.0% share in 2021, over the five-year average of 10.8% and ten-year average of 8.4%, followed by Pakistan with a 10.0% share, compared with the five-year and ten-year averages of 1.0% and 1.1% respectively.

Taiwan held a 10.0% share in 2021, as against the five-year average of 2.3% and ten-year average of 2.2%.

Spain held a 5.0% share in 2021, over the five-year average of 2.2% and ten-year average of 3.0%.

Phase I trials lead industry sponsored clinical trials for Hepatitis C in 2021

Phase I trials held an 86.7% share of industry sponsored clinical trials for Hepatitis C in 2021, over the five-year average of 43.1% and ten-year average of 41.4%.

Phase II trials held a 6.7% share in 2021, as against the five-year average of 19.8% and ten-year average of 22.8%. Phase III trials held a 6.7% share in 2021, compared with the five-year and ten-year averages of 15.4% and 20.5% respectively.

Phase IV trials held a 0.0% share in 2021, over the five-year average of 21.8% and ten-year average of 15.3%.

Phase IV trials lead non-industry sponsored clinical trials for Hepatitis C in 2021

Phase IV trials held a 60.0% share of non-industry sponsored clinical trials for Hepatitis C in 2021, over the five-year average of 49.4% and ten-year average of 42.7%.

Phase I trials held a 15.0% share in 2021, as against the five-year average of 9.1% and ten-year average of 8.3%. Phase II trials held a 15.0% share, compared with the five-year and ten-year averages of 30.0% and 37.2% respectively.

Phase III trials held a 10.0% share in 2021, over the five-year average of 11.4% and ten-year average of 11.7%.

Methodology: The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena